NCT05700045 is a NA clinical trial of Dexmedetomidine in Multimodal Analgesia, sponsored by Xijing Hospital.

Who is sponsoring NCT05700045?

NCT05700045 is sponsored by Xijing Hospital.

What drugs are being tested in NCT05700045?

Interventions in NCT05700045: Dexmedetomidine.

What condition does NCT05700045 study?

NCT05700045 studies Multimodal Analgesia, Cesarean Section.

Is NCT05700045 still recruiting?

NCT05700045 is currently completed. Last updated 11 October 2023.

Last reviewed 2023-10-11 · How we verify

NCT05700045

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TAP Using Dexmedetomidine and Ropivacaine for Cesarean Section Analgesia

Completed NA Last updated 11 October 2023

What this trial tests

NA trial testing Dexmedetomidine in Multimodal Analgesia in 90 participants. Completed in 30 September 2023.

Timeline

31 May 2023

Primary endpoint
28 September 2023

30 September 2023

Quick facts

Lead sponsor	Xijing Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	90
Start date	31 May 2023
Primary completion	28 September 2023
Estimated completion	30 September 2023
Sites	2 locations across China

Drugs / interventions tested

Dexmedetomidine (dexmedetomidine) — full drug profile →

Conditions studied

Multimodal Analgesia — all drugs for Multimodal Analgesia →
Cesarean Section — all drugs for Cesarean Section →

Sponsor

Xijing Hospital

Who can join

18 and older, female only, with Multimodal Analgesia or Cesarean Section. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the effect of dexmedetomidine as an adjuvant of ropivacaine in the TAP block on cesarean section parturients under multimodal analgesia, optimize the multimodal analgesia program for cesarean section, and guide perioperative analgesia managemen。This is a single center, double-blind, randomized clinical trial.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Dexmedetomidine as adjuvant of transversus abdominal plane block for cesarean delivery under multimodal analgesia: a randomized clinical trial.
Wang Y, Wang L, Wang Y, Mu X, et al · · 2026 · PMID 41578187 · DOI 10.1186/s12871-026-03642-0

Verify or expand the search:

Other trials of Dexmedetomidine

Trials testing the same drug.

NCT06824077 — Reducing Days DELirious With DEXmedetomidine as Part of an Intensive Care Unit Sleep Promotion Bundle · EARLY_PHASE1 · not yet recruiting
NCT07398066 — DEXmedetomidine for Postoperative Analgesia and Delirium Prevention After NEUROsurgery (DEX-NEURO Trial) · NA · not yet recruiting
NCT07377981 — An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyp · Phase 4 · not yet recruiting
NCT07306702 — Dexmedetomidine-Enhanced PCIA After Lobectomy in Nicotine-Dependent Patients · Phase 4 · withdrawn
NCT07482540 — Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery · NA · not yet recruiting

Other recruiting trials for Multimodal Analgesia

Currently open trials in the same condition.

NCT07427043 — Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES) · Phase 3 · recruiting
NCT07226700 — Suzetrigine in Total Hip Arthroplasty · Phase 3 · recruiting
NCT06819748 — Efficacy and Safety of Cocktail of Ropivacaine for Local Infiltration Analgesia in Patients Undergoing Laparoscopic Chol · NA · recruiting
NCT06563349 — Magnesium Sulfate in Children Undergoing Laparoscopic Appendectomy · Phase 4 · recruiting

Other Xijing Hospital trials

Trials by the same sponsor.

NCT07532096 — Extended Sentinel Lymph Node Biopsy With Methylene Blue Single Tracer Post-Neoadjuvant Therapy for Node-Positive Breast · NA · not yet recruiting
NCT07519018 — TIS for Drug Resistant TLE · NA · not yet recruiting
NCT07518992 — Correlation Between Preoperative Sleep and Postoperative Brain and Renal Dysfunction · not yet recruiting
NCT07466303 — Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07474142 — A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve P · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05700045 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xijing Hospital
Last refreshed: 11 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05700045.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing